Combined radio-immunotherapy improves treatment outcome in mouse model for BRAF-mutated melanoma


Recent developments in immunotherapy have meant big breakthroughs for patients with advanced melanoma. Treatment with immunotherapy drugs like anti-PD-1 or anti-CTLA4 antibodies is quite successful in many of these patients. Still, forty to fifty percent of them do not benefit from these drugs. A team led by Netherlands Cancer Institute researchers Inge Verbrugge and Christian Blank tried out several combinations of immunotherapy and radiotherapy in a mouse melanoma model, to see whether theses therapies can enhance each other.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.